Overcoming obstacles with LAMA
TRI shares just one of the features of Thalocan’s Lesion Area Mapping Assistant (LAMA) – revolutionizing clinical assessment of HS, among other indications. Learn more at: https://www.thalocan.com/lama/
Read article
Conversations with Portia Combow – “What has been your experience with clinical studies?”
The fourth in our series of Conversations with Portia Combow and living with HS. Thalocan Research Innovations CEO Eric Zudak and Portia discuss the roadblocks she’s encountered with clinical studies. Watch the full webinar/conversation at www.thalocan.com/webinars/.
Why We Built Thalocan: The Forgotten Links in Dermatology Clinical Trials
Why We Built Thalocan: The Forgotten Links in Dermatology Clinical Trials Interview with Eric Zudak, CEO of Thalocan Research Innovations by Ginger Claremohr, Claremohr Writing Co. There’s a moment in every startup story when frustration turns into fuel. For Eric Zudak, founder of Thalocan Research Innovations, that moment came when a global pharmaceutical company called…
Revolutionizing Lesion Assessment for Hidradenitis Suppurativa
Old school paper record keeping is time-consuming with a higher potential for missteps. Avoiding this is just ONE of the many reasons we designed LAMA. A patent-pending, BYOD cloud-based solution, Thalocan’s Lesion Area Mapping Assistant (LAMA) is built on a single concept: improve lesion assessment during dermatologic clinical trials with a streamlined, comprehensive and structured…